Slingshot members are tracking this event:

FDA Grants Breakthrough Therapy Status to Novartis' (NVS) CTL019 in Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 18, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda, Breakthrough Therapy Status, Ctl019, Refractory Diffuse Large B Cell Lymphoma, R/r Dlbcl